To all:
Is it time to re-invigorate this thread?
Biotech stocks are rapidly approaching their all time highs again. The peak of the NASDAQ biotech index was achieved in late February at 355. In late April, it stood at 270 (20% correction). It has now returned to 320.
In the meantime, we have seen some great blow-ups (I wish I had had the courage to short them all).
AIMM (Autoimmune) - $16 - $2. Oh well, oral tolerance doesn't work.
BZET (Biofield) - $18 - $4. Still some life in this one.
VVUS (Vivus) - $80 - $30 (and back to $50). Very controversial, definitely not for this thread.
There are more, but I would contend that the valuations are reaching absurd and UNSUSTAINABLE levels.
Remember last summer's drop was from 336 to 252 (25%).
Now someone must have some good ideas out there. And for those who think shorting is anti-American or whatever, what could be more capitalistic than getting a 25% profit in a few months.
My ideas:
VVUS - see VVUS thread
VIRS - I still think this puppy is grossly overvalued (see thread).
QGENF - Great products. But a P/E multiple of 100??
HMSC - Humascan (you have to check this out). Thermographic pads for detection of breast cancer that don't work as well as mammography, are not reimbursed, and have been around for years.
NRLD - Norland. #3 seller of bone-densitometers (#1 HOLX, #2 LUNR). The corporate structure of NRLD appears to be designed for the maximum benefit of the CEO. In a not-so "arm's length" transaction, the CEO is buying himself out for $16 million. It's complicated, but I can explain if someone desires.
Kafka666.
P.S. I am long TXB, IDPH, and XOMA (so there). |
